Loading
Indivior Pharmaceuticals, Inc. Stock: price and insider trades · United States
1 insider bought €93k of shares over the last 90 days, the latest by Anderson Woodrow D, filed 27 Aug 2026.
Insider Decl.
42
Thresholds
n/a
Buy Volume
€120,000
5 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleBarbara Ryan2 buys
Woodrow D. Anderson2 buys
Stuart A. Kingsley1 buy
Since the insiders bought
- +0.1%Entry US$34.87 · Close 21 Oct 2026 US$34.92
- +24.2%Entry US$30.97 · Close at T+90 US$38.48
- +23.4%Entry US$30.86 · Close at T+90 US$38.09
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,974 of 26,248 companies
61.4
score / 100
Value43
Quality80
FCF yld-2.3%
Earn yld5.1%
EV/EBITDA14.7x
ROE·
Gross mgn80%
Net mgn17%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$34.79
Analyst consensus
4 analysts1.25/5
US$43.00Target US$49.00(+41%)US$53.00
Income statement
RevenueUS$1.2B
Gross profitUS$993M80% margin
EBITDAUS$304M25% margin
Net incomeUS$210M26.7% margin
Valuation
PER (trailing)12.5x
PER (forward)7.1x
Beta1.18
Balance sheet & cash
Market capUS$4.1B
Total debtUS$351M
Free Cash Flow-US$94M
Profitability & ownership
ROA26.4%
% insiders1.8%
% institutions104.8%
Last declaration on 27 August 2026
Declarations42 total
1,500 shares@ US$35.690.0012% mcap100.0% of flowCommon StockSEC:0002014440-26-000012:0
Canonical exit: 25 Nov 2026 (T+90)
1,500 shares@ US$36.280.0013% mcap100.0% of flowCommon StockSEC:0002014440-26-000010:0
Canonical exit: 3 Nov 2026 (T+90)
18,586 shares@ US$41.140.018% mcap52.2% of flowCommonSEC144:0001959173-26-005188
1,266,903 sharesCommon StockSEC:0001443841-26-000007:0
612,549 sharesCommon StockSEC:0001443841-26-000007:1
18,586 shares@ US$38.060.015% mcap47.8% of flowCommonSEC144:0001959173-26-004549
36,000 shares@ US$37.700.028% mcap33.0% of flowCommonSEC144:0001959173-26-004422
6,518 shares0Common StockSEC:0001487937-26-000009:0
6,518 shares0Common StockSEC:0001827169-26-000013:0
10,430 shares0Common StockSEC:0001789507-26-000008:0
6,518 shares0Common StockSEC:0001257599-26-000008:0
6,518 shares0Common StockSEC:0002014900-26-000009:0
6,518 shares0Common StockSEC:0001369067-26-000009:0
1,117 shares@ US$38.280.0008% mcap100.0% of flowCommon StockSEC:0001715258-26-000007:0
2,843 shares@ US$31.112.1% of flowCommon StockSEC:0002014866-26-000008:1
6,302 sharesCommon StockSEC:0002014866-26-000008:0
8 shares@ US$31.08519.8% of flowCommon StockSEC:0001827169-26-000010:0
Canonical exit: 11 Jun 2026 (T+90)
31 shares@ US$32.5680.2% of flowCommon StockSEC:0001827169-26-000008:0
Canonical exit: 7 Jun 2026 (T+90)
940 shares@ US$31.865100.0% of flowCommon StockSEC:0001369067-26-000006:0
Canonical exit: 4 Jun 2026 (T+90)
5,946 sharesCommon StockSEC:0002014440-26-000007:2
8,283 shares@ US$31.9857.6% of flowCommon StockSEC:0002014440-26-000007:1
86,949 sharesCommon StockSEC:0002014866-26-000006:1
2,682 shares@ US$31.9818.7% of flowCommon StockSEC:0002014440-26-000007:3
36,032 shares@ US$31.98100.0% of flowCommon StockSEC:0001484322-26-000013:1
45,797 shares@ US$31.9849.5% of flowCommon StockSEC:0002014639-26-000006:1
25 of 42 declarations
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc., a US healthcare company worth USD 4.0 billion, has a record of a single year, 2026: 42 filings from 15 filers, including 27 grants, 7 option exercises and 3 filings of another kind. Insiders hold 1.8% of the capital. It contains no sale, and 5 purchases worth EUR 120,000 in total, with a median of EUR 25,804.
Woodrow D. Anderson, Chief Accounting Officer, bought EUR 47,193 on August 5, 2026 then EUR 45,912 on August 27, 2026, and has 7 filings including 2 purchases. Stuart A. Kingsley, a director, bought EUR 25,804 on March 6, 2026. Two insiders bought from March 6, 2026 to March 13, 2026, for EUR 26,895. Barbara Ryan, a director, also lodged 4 filings including 2 purchases, and Joseph Ciaffoni, Chief Executive Officer, 3 with neither purchase nor sale.
Read moreShow less
The median publication delay is 2 days. The last twelve months cover the whole record: 42 filings, 5 purchases, no sale. The history is too short to draw more than these facts.
